Evaluation of Anti-Angiogenic Effect of Naturally Occurring Compound from Ficus.Bengalensis on Regeneration & Development of Zebra-Fish Fin

Authors

  • uday kundap

  • sadhanasathaye

  • kamble rachana

  • ketan uict

  • pdjain23

Abstract

Angiogenesis is the process that leads to the formation of new blood vessels or neovascularisation. Angiogenesis inhibitors are designed to prevent the formation of new blood vessels. The main aim of this study is to evaluate Anthocyanin obtained from medicinal plant Ficus.bengalensis for Anti-angiogenesis & to standardize a method for the study of angiogenesis. A variety of animal models have been described to provide more quantitative analysis of in vivo angiogenesis and to characterize pro- and anti Angiogenic molecules. However, it is still necessary to establish a quantitative, reproducible and specific method for studies of angiogenesis factors and inhibitors. In-vivo animal models were used, Anti-Angiogenic effects on Zebrafish fin regeneration. Parameters observed were Regenerative angiogenesis & variation in Zebrafish fin. In regenerative angiogenesis, test drug shows inhibition of fin regeneration as compared to Control Group. We demonstrate that the zebrafish is a viable model for screening small molecules that can inhibit angiogenesis. corroborating to the validity of the standardized method, Studies support and accelerate the application of Zebrafish & model that predict the anti- Angiogenic potential value of compound.

Downloads

How to Cite

Evaluation of Anti-Angiogenic Effect of Naturally Occurring Compound from Ficus.Bengalensis on Regeneration & Development of Zebra-Fish Fin. (2015). Global Journal of Medical Research, 15(10), 9-19. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Author Biography

uday kundap

Pharmacy graduate with Ph.D in Neuropharmacology and toxicology with proven ability to work independently and navigate competing priorities, and recent evidence of training in clinical research standards. My previous jobs have prepared me with critical thinking ability and risk management with excellent presentation skills. With over 5 years of collective experience as a Clinical Scientist / Manager at various research organizations, I have an ability to make & communicate difficult decisions, associated with strong written and verbal communication skills. I am interested in drug discoveries, clinical research, clinical trial monitoring and have more than 6 years of experience in projects related to clinical trials and BA-BE studies for investigational drugs, ethical submission, eCRF, eSAE reporting, ICH-GCP, ICH-GMP, GLP. As a Clinical Research Scientist at Horizon Health Network, specializing in oncology research with a focus on lung cancer. I lead the design and execution of clinical study protocols, translating scientific insights into innovative treatment strategies that enhance patient outcomes and drive impact across the healthcare system. My current work centers on decentralized clinical trial models for lung cancer therapies-ensuring medical risk-benefit assessments are aligned with patient-centered care, while also aiming to reduce the financial burden on the healthcare system. As a co-applicant (STITCH-01 project with Roche Canada) I have successfully secured $75,000 CAD in research funding from ResearchNB (New Brunswick, Canada), and I’m proud to collaborate with leading industry partners, including Roche Canada, Abbvie Canada and AstraZeneca, to advance this vital research. Experience working as a Clinical and Regulatory Manager at Triple Hair Inc. for Phase-3 studies related to Decentralized Androgenic Alopecia, product launch, Study design and Regulatory affairs. Previously worked as Clinical Research Coordinator for Canada East Spine Centre at Saint John Regional Hospital for studies related to Shoulder reconstruction therapy, Spine Fusion and Neurosurgery. Sr. Post-Doctoral scientist at Pierre Drapeau-Eric Samarut’s research lab at The University of Montreal Hospital Centre (CRCHUM), Montreal, Canada for projects related to precision medicine for epilepsy, drug discoveries, pre-clinical model development, qPCR, genetic mutation in zebrafish animals, product development. My previous project was more focused on 'Development of the zebrafish model by genetic modification, discovery of targeted anti-epileptic drug treatment for specific epilepsy and development of precision medicine in rare genetic epilepsy patients. I have received a prestigious FRQS funding of CAD 135,000$ from Govt. of Quebec for my post-doctoral fellowship (PDF) 2019-2022. During my PhD and PDF I have won various national and International awards and travel grants (worth US 10,000$) in the field of epilepsy and neuroscience.

References

Amy Rubinstein (2003) Zebrafish: From disease modeling to drug discovery". Zygogen LLC 520 Kell Hall 24 Peachtree Center Avenue Atlanta GA 30303 USA e-mail: amy@zygogen. 6(2), 218-223.

D. Bagchi, C. Sen, M. Bagchi, M. Atalay (2004) Anti-angiogenic, Antioxidant, and Anti-carcinogenic Properties of a Novel Anthocyanin-Rich Berry Extract Formula. 69(1), 75-80.

E. Barcz, E. Sommer, P. Janik, L. Marianowski, E. Skopinska-Rózewska (2000) Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells. 7(6), 1285-1291.

Christian Lawrence (2007) The husbandry of zebrafish (Danio rerio): A review. 06-004.

Fraysse B, Mons R, Garric J Development of a zebrafish 4-day embryo-larval bioassay to assess toxicity of chemicals. 63, 253-267.

Fishman MC (1999) Zebrafish genetics: The enigma of arrival. 96, 0554-1055.

Gael McGill, &. David, E. Fisher Apoptosis in Tumorigenesis & Cancer therapy.

Han-Chung Wul, De-kaun Chang, chia-Ting, Chia-ting Huang Targeted Therapy for Cancer.

H. Vogel Drug Discovery and Evaluation Pharmacological Assays. 3-540.

John Abelson, Aelvini Simon (2008) METHODS IN ENZYMOLOGY. 2008, 149-153.

Charles Kimmel, William Ballard, Seth Kimmel, Bonnie Ullmann, Thomas Schilling (1995) Stages of embryonic development of the zebrafish, DevDyn 1995. 203(3), 253-310. https://doi.org/10.1002/aja.1002030302

L. Jensen1 Animal Models of Angiogenesis and Lymphangiogenesis. 1.

M. Malin Dollinger, Ernest Rosenbaum, Margaret Tempero, M., Sean Mulvihill, Everyone Everyone's guide to CANCER THERAPY.

J. Oszmianski, C. Lee (1990) A description of methods for isolating polyphenolics and Anthocyanin from grapes by solid-phase extraction.

SimonaLucioli (2012) Anthocyanin: Mechanism of action and therapeutic efficacy. 2012, 27-57.

Sameer Sheikh Anis, Mandorianarendra singh (2012) Sheikh Anis, Sameer singh, Mandoria Narendra, "A Review on Phytopharmacological Aspects of Ficus bengalensis, Institute of Pharmacy, ujjain. 4(06), 18-022.

Kurt Seng WL, McGrath Lee J (2004) Use of a monoclonal antibody specific for activated endothelial cells to quantitate angiogenesis in vivo in zebrafish after drug treatment. 7, 243-253.

*. Uday P Kundap, Rachanasarawade (2013) Recent Potent Molecular Targets for Cancer Treatment - A Review. 04(04), 790-808. http://www.ijpba

M. Westerfield (2000) The Zebrafish Book, Guide for the Laboratory Use of Zebrafish (Danio rerio). 4th Ed Eugene.

R. Wrolstad, G. Skrede, P. Lea, G. Enersen Extraction, Isolation, and Purification of Anthocyanin.

Published

2015-03-25

How to Cite

Evaluation of Anti-Angiogenic Effect of Naturally Occurring Compound from Ficus.Bengalensis on Regeneration & Development of Zebra-Fish Fin. (2015). Global Journal of Medical Research, 15(10), 9-19. https://medicalresearchjournal.org/index.php/GJMR/article/view/